KHC — The Kraft Heinz Company

The market is not treating KHC as a distressed liquidation story, but it is also not paying up for a turnaround. Wall Street average consensus is Hold, with 20 Holds, 11 Sells, and only 4 Buys, and the 2026-08-27 price of $25.13 sits above the consensus target of $22.75 and recent average target of $23.83. The positive FCF, 7.1% dividend yield, and cheap trading multiples are offset by persistent volume declines, two massive impairment charges over the past four quarters, and management's still-unproven growth plan.

Revenue has been grinding lower at a low-single-digit rate for the past three years: YoY quarterly revenue changes were around -2.9%, -4.1%, -6.4%, -1.9%, -2.3%, -3.4%, +0.8%, and -1.4% from Q3 2024 through Q2 2026. That is a structural grind, not a one-quarter blip. Reported EPS is unreliable because Q2 2025 included a -$7.82B net charge and Q2 2026 included a -$5.46B net charge, creating diluted EPS of -$6.57 and -$4.60 in those quarters. Normalized earnings power looks closer to $2.0-$2.3 per share, and gross margin has slipped from roughly 34-35% in 2024 to around 32-33% in 2026, reflecting cost inflation and promotional pressure. Underlying operating margins excluding impairments remain in the mid-to-high teens, but the direction of travel is not inflecting upward.

As of 2026-08-27, trailing P/E of -8.8x is meaningless because of impairment losses. The more useful numbers are the forward ones: at $25.13, KHC trades at roughly 12.2x the next-FY consensus EPS estimate of $2.053, which is well below packaged foods at ~15.6x, consumer staples at ~17.6x, and the S&P 500 at ~20.3x. Price-to-sales is 1.20x versus a five-year average nearer 1.57x, price-to-book is 0.83x, and the dividend yield is 7.1%. That looks cheap on a multiple basis, but the discount is justified by negative volumes, promotional intensity, and an overhang of possible further write-downs. The honest read is fair-to-cheap, not a clear bargain.

The current price is not pricing in a sharp earnings recovery; it is basically paying a fair, undemanding multiple on consensus forward earnings. The playbook is not 'buy the obvious undervalued turnaround' but 'wait for evidence that North American volume/mix is stabilizing.' If KHC can hold EPS near $2.05 and stabilize market share, $25 is defensible. If volume erosion continues, the stock likely re-rates toward the low-$20s or worse, because a 7% dividend yield alone will not hold the floor if cash generation starts to weaken. Earnings estimates are already conservative enough that a beat is possible, but no positive inflection is currently visible in the data.

As of 2026-08-27, RSI was 48.19, squarely in neutral territory. Price was 0.91% below the 20-day SMA, essentially right at the 50-day SMA (+0.15%), and 4.7% above the 200-day SMA. That is a range-bound, momentum-free setup. The 52-week range is $21.04-$28.09, and $25.13 sits in the middle, so there is no oversold bounce signal and no breakout signal. For entry timing, this stock is neither washed-out nor breaking down; it looks like a grind-around-and-wait chart.

• Lower SNAP benefit outlays are estimated to create roughly a 100bps structural headwind for U.S. retail food demand, hitting value-oriented packaged-food portfolios.
• Consumer staples volumes are broadly contracting as shoppers push back on years of cumulative price increases, forcing brands into heavier promotional spending.
• Full-year 2026 input-cost inflation of about 4% is compressing gross margin unless pricing and productivity more than offset it.
• Elevated interest rates make KHC's 7.1% dividend yield less distinctive versus risk-free alternatives and raise the cost of refinancing its ~$17.6B long-term debt.
• Private-label share gains and retailer price competition remain a structural risk for mid-tier packaged-food brands like Kraft and Oscar Mayer.

• September 2026 transition to NYSE listing, which management hopes will broaden institutional ownership and index-related demand.
• Q3 2026 earnings in late October/early November 2026, which will show whether North American volume/mix declines are moderating.
• International and health-focused innovation pipeline, especially the European testbed strategy, could provide a genuine growth narrative if scaled successfully.
• Dollar-share stabilization of the portfolio (currently around 36%) would be an early sign that increased marketing spend is working.

• Persistent North American volume decline — Q2 2026 volume/mix fell 3.8% in North America — suggests the core business is still losing relevance and shelf space.
• Additional goodwill or brand impairment charges remain possible after the massive Q2 2025 and Q2 2026 write-downs; balance-sheet marks can keep resetting lower.
• Dividend sustainability is okay today given ~$3.8B TTM free cash flow versus roughly $2.1B of dividends, but a prolonged earnings slide would make the 7.1% yield feel less safe.
• Inflation and promotional spending could keep pressuring gross margin, especially if pricing power continues to fade.
• The company is carrying meaningful leverage ($17.6B long-term debt, 0.53 debt-to-equity) in a higher-for-longer rate environment.

KHC is not a compelling buy or a high-conviction short right now. It is a high-cash-generative, no-growth consumer staple trading at a reasonable forward multiple with a fat dividend, but the core North American franchise is still losing volume and management has not yet proven a credible reacceleration story. This is a hold/income vehicle, not a turnaround investment, until organic sales and market-share trends inflect positively.

Calculated by applying a 12.0x forward P/E to the next-fiscal-year consensus EPS of $2.053. The 12.0x multiple is a deliberate discount to the packaged-food peer group of ~15.6x, justified by flat-to-negative organic volume, promotional intensity, and the risk of further write-downs; this yields a fair value of approximately $24.64, modestly below the 2026-08-27 price of $25.13.